GlassScriptPhysician profile
Bharat Pothuri
NPI 1023187614
$15,650.35
in general payments reported to CMS, 2019-2025
38 companies · $9,684 in 2025
The $9,684 reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $676 · 2021: $864 · 2022: $960 · 2023: $640 · 2024: $1,890 · 2025: $9,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,460 · Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,460.00 |
| Food and Beverage | $2,753.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $10,143.83 | 2024-2025 | Voquezna |
| Abbvie INC. | $954.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $874.98 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $477.52 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $447.33 | 2019-2025 | General - Therapies, Resolution 360 Clip |
| Celgene Corporation | $430.11 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $216.96 | 2019-2023 | Suflave, Sutab |
| Genzyme Corporation | $216.88 | 2022-2025 | |
| Gilead Sciences, INC. | $165.45 | 2019 | |
| Qol Medical, LLC | $141.89 | 2019-2023 | Sucraid |
| Allergan, INC. | $124.50 | 2019-2020 | |
| Redhill Biopharma INC. | $118.17 | 2021-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $118.16 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $116.89 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $111.89 | 2020-2024 | Tremfya |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.39 | 2020 | |
| Lilly USA, LLC | $107.30 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $103.54 | 2021 | |
| Ardelyx, INC. | $76.12 | 2024 | Ibsrela |
| Conmed Corporation | $57.50 | 2023-2025 | Conmed Hemostasis, Conmed Biliary |
| Pfizer INC. | $54.83 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $51.04 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $42.09 | 2021-2024 | |
| Medtronic, INC. | $39.77 | 2021-2024 | Nexpowder |
| Shire North American Group INC | $38.38 | 2019 | |
| Covidien LP | $37.81 | 2020 | |
| Ethicon US, LLC | $37.80 | 2020 | |
| Evoke Pharma, INC. | $35.32 | 2021-2023 | Gimoti |
| Enterra Medical, INC. | $27.35 | 2023 | |
| Mauna Kea Technologies, INC. | $26.82 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.97 | 2023 | Andexxa |
| Regeneron Healthcare Solutions, INC. | $21.61 | 2023 | Dupixent |
| Celltrion USA INC. | $21.36 | 2024 | Vegzelma |
| Romark Laboratories, Lc | $18.50 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.36 | 2025 | Iqirvo |
| Alexion Pharmaceuticals, INC. | $16.27 | 2019 | |
| Cook Medical LLC | $16.14 | 2024 | Zilver Ptx |
| Pentax of America, INC. | $15.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharat Pothuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.